Keyphrases
Anatomical Variation
12%
Autoantibodies
31%
Autoimmune Disease
65%
Autoimmune Response
10%
Autoimmune Thyroiditis
10%
Autoimmunity
62%
Autoinflammatory Conditions
12%
Clinical Features
14%
Clinical Manifestations
7%
Clopidogrel
12%
Closure Time
7%
Cluster Analysis
9%
Colombia
13%
Colombians
14%
Convalescent Plasma
35%
Convalescent Plasma Therapy
7%
COVID-19
71%
COVID-19 Vaccination
10%
Disease-based
12%
High On-treatment Platelet Reactivity
12%
Hospitalization
8%
Hospitalized Patients
17%
Immune Response
8%
Immunological Characteristics
11%
Immunological Effects
7%
Interleukin-6
14%
Latent Autoimmunity
9%
Mechanism of Action
7%
Meta-analysis
23%
Molecular Mimicry
8%
New Taxonomy
9%
Next-generation Sequencing
12%
Patients with COVID-19
18%
Pharmacological Analysis
12%
Platelet Reactivity
12%
Poly(A)
7%
Polyautoimmunity
57%
Post-COVID Syndrome
32%
Post-COVID-19
7%
Primary Biliary Cholangitis
13%
Primary Immunodeficiency
12%
Rheumatoid Arthritis
12%
Severe Coronavirus Disease 2019
12%
Single nucleotide Polymorphism
7%
Systematic Meta-analysis
19%
Systemic Lupus Erythematosus
13%
Systemic Sclerosis
10%
T Cells
9%
Type 1 Diabetes Mellitus (T1DM)
14%
Type I Diabetes
14%
Immunology and Microbiology
Antigen Specificity
6%
Autoantibody
32%
Autoimmune Disease
48%
Autoimmune Hepatitis
6%
Autoimmune Rheumatic Disease
6%
Autoimmune Thyroiditis
12%
Autoimmunity
100%
Blood Plasma
25%
CD137 Ligand
5%
COVID-19
93%
Cytokine
14%
Ebola Virus
6%
Immune Dysregulation
6%
Immune Response
8%
Immune Tolerance
8%
Immunodeficiency
12%
Immunoglobulin G3
6%
Immunosuppressive Drug
6%
Inflammatory Arthritis
13%
Interleukin 6
12%
Molecular Mimicry
7%
Peptides
5%
Prevalence
15%
Primary Biliary Cirrhosis
6%
Primary Immunodeficiency
13%
Regulatory T Cell
10%
Rheumatic Polymyalgia
6%
SARS Coronavirus
6%
Severe Acute Respiratory Syndrome Coronavirus 2
17%
Systemic Lupus Erythematosus
14%
Systemic Scleroderma
13%
T Cell
20%
Thyroid
9%
TLR4
6%